SEC Form 4 · accession 0001127602-15-027731
ARIAD PHARMACEUTICALS INC · ARIA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Frank Haluska
Officer — SVP, Clinical R&D, CMO
Period of report
Sep 24, 2015
Accepted (ET)
Sep 28, 2015 · 5:40 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000884731
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Sep 24, 2015 | M | 10,000 | $0.00 | A | 127,724 | D | |
| Common StockF3 | Sep 28, 2015 | S | 5,500 | $6.455 | D | 122,224 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Performance stock unitF4,F5 | — | Sep 24, 2015 | M | 10,000 | D | — | — | Common Stock | 10,000 | 10,000 | D |
| Performance stock unitF4,F5 | — | Sep 24, 2015 | A | 20,000 | A | — | — | Common Stock | 20,000 | 20,000 | D |
Explanation of responses
- F1Shares were acquired upon vesting of performance stock units awarded on March 19, 2013.
- F2Represents shares sold to satisfy withholding tax requirements, pursuant to a Rule 10b5-1 trading plan.
- F3The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.22 to $6.72, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Security and Exchange Commission, upon request, full information regarding the shares sold at each separate price within the range set forth in this footnote.
- F4Each performance stock unit represents a right to receive one share of ARIAD common stock.
- F5The performance stock units vest as to 50% of the award on 9/24/15 and 50% of the award on 9/24/2016.